Ohio State Navbar

Research

Research Grants


Current Research Grants

 

Sponsor: NIH/NCI SAIC
PI: Jas Lang, PhD
Title: Frederick Cancer Genome Atlas Project (TCGA) BOA 13XS121
Period: 03/26/2013-Present
Goal: The goal of this study is to function as a Tissue Source Site (TSS) to process and provide specimens of head nd neck squamous cell carcinoma and matched blood samples for the TCGA project.
   
Sponsor:  NIH/NCI-R01CA193590
PI:  Quintin Pan, PhD
Title:  Cancer Initiating Cells and Treatment Resistance Total Project
Period:  04/08/2015-03/31/2020
   

Sponsor:

NIH/NIDCR-R01DE023555
PI: Quintin Pan, PhD

Title:

Role of p300 in HPV-positive Head and Neck Cancer     
Period: 05/06/2015-04/30/2020
   
Sponsor:  NIH/NIGMS-R01GM117921
Co-PI:  Quintin Pan, PhD
Title:  p53/Rb Reactivation Modulators for HPV-positive Head and Neck
 Cancer
Period:  2/01/2016-1/31/2020
   
Sponsor:  NIH/NIDCR-R01DE022087
Co-PI:  Quintin Pan, PhD
Title:  Bcl-2 as a biomarker for prognosis and therapy of head and neck
 cancer
Period:  7/01/2011-4/30/2017
   
Sponsor:  National Comprehensive Cancer Network
Co-PI:  Quintin Pan, PhD
Title:  Use of Vorinostat for Definitive Treatment of Advanced Stage
 Oropharyngeal Squamous Cell Carcinoma             
Period:  02/01/10-05/31/16
   
   

 


Clinical Trials for Head and Neck
 

Phase III Randomized, Open-Label, Multicenter, Global Study of MEDI4736 Alone or in Combination With Tremelimumab vs. Standard of Care in the Treatment of First-Line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
(OSU-15210) Maura Gillison, MD, PhD

Phase I/II Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
(OSU-16120) Maura Gillison, MD, PhD

Randomized, Phase III Trial of Cisplatin-Based Chemotherapy (CRT) +/- Nivolumab (ANTI-PD-1) in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (with Phase I Lead in)
(RTOG-3504) Maura Gillison, MD, PhD

Open-Label, Randomized, Two-Arm Phase III Study of Nivolumab in Combination With Ipilimumab vs. Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
(OSU-16134) Maura Gillison, MD, PhD

Open-Label, Multicenter Phase I/II Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
(OSU-16147) Maura Gillison, MD, PhD

 

 


Past Head and Neck Research Grants

Use of vorinostat for definitive treatment of advanced stage orophayngeal squamous cell carcinoma
PI: Ted Teknos, MD
2010-2014
National Comprehensive Cancer Network
 

 



Role of tumor-associated enothelial cells in chaperoning tumor cells
PI: Pawan Kumar, MS, PhD
07/02/2014-06/30/2016
NIH/NCI
 


James Rocco, MD, PhD

07/01/2011-04/30/2016

NIDCR/NCI

BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer

R01DE022087-01

The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).

 

James Rocco, MD, PhD

07/01/2011-04/30/2016

NIDCR/NCI

BCL-2 as a Biomarker for Progrnosis and Therapy of Head and Neck Cancer

R01DE022087-01

The major goal of this project is to assess the role of functional Bcl2 status in predicting response to chemo-radiation therapy using the novel technique of BH3 profiling for the first time in oropharyngeal squamous cell carcinoma (OPSCC).